2. Search Result
Search Result
Results for "

HY-10218

" in MedChemExpress (MCE) Product Catalog:

4

阻害剤およびアゴニスト

2

同位体標識化合物

製品番号 製品名 Target 研究分野 構造式
  • HY-10218
    Everolimus
    110+ Cited Publications

    RAD001; SDZ-RAD

    		 mTOR FKBP Autophagy Apoptosis Bacterial Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus
  • HY-10218S
    Everolimus-d4

    RAD001-d4; SDZ-RAD-d4

    		 mTOR FKBP Autophagy Apoptosis Cancer
    Everolimus-d4 is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus-d4
  • HY-10218R
    Everolimus (Standard)

    RAD001 (Standard); SDZ-RAD (Standard)

    		 Reference Standards mTOR FKBP Autophagy Apoptosis Bacterial Cancer
    Everolimus (Standard) is the analytical standard of Everolimus. This product is intended for research and analytical applications. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus (Standard)
  • HY-10218S1
    Everolimus-13C2,d4

    RAD001-13C2,d4; SDZ-RAD-13C2,d4

    		 Isotope-Labeled Compounds Bacterial Autophagy FKBP mTOR Apoptosis Cancer
    Everolimus- 13C2,d4 (RAD001- 13C2,d4) is 13C labeled Everolimus. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus-13C2,d4

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: